Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
MRI, with or without targeted biopsy, detects more clinically significant prostate cancer and less clinically insignificant prostate cancer than the standard transrectal ultrasonography (TRUS)-guided approach, enabling more than one-quarter of patients to safely avoid a biopsy altogether.
Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.
Patients with urologic cancers are more likely to attempt suicide, highlighting the need for increased psychiatric intervention for these patients at an earlier stage, according to findings presented at the European Association of Urology (EAU) 2018 Congress.
The androgen receptor inhibitor apalutamide prolonged metastasis-free survival (MFS) by approximately 2 years in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastatic disease, according to findings of the SPARTAN* trial.
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Researchers have developed a new polygenic hazard score, which has been validated by an independent dataset, for assessing personalized genetic risk that can predict age at onset of aggressive prostate cancer, reports a study.
Treatment with enzalutamide has maintained its antitumour activity in patients with hormone-naïve prostate cancer at 3 years, according to a recent study. In addition, overall bone mineral density, global health status and safety results are comparable to those at 2 years.
Compared with the anterior approach to the prostate, Retzius-sparing-robot-assisted radical prostatectomy is faster, allows a shorter catheterization time, and delivers better continence results at 4 weeks, with most patients being pad-free or needing just a single pad a day, a recent study has shown.